tyrosine has been researched along with Achondroplasia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baruzzi, A; Ferrarini, F; Liboi, E; Lievens, PM; Montone, R; Romanelli, MG | 1 |
| Crooke, A; Guzmán-Aránguez, A; Pintor, J; Yayon, A | 1 |
2 other study(ies) available for tyrosine and Achondroplasia
| Article | Year |
|---|---|
Mutant FGFR3 associated with SADDAN disease causes cytoskeleton disorganization through PLCγ1/Src-mediated paxillin hyperphosphorylation.
Topics: Achondroplasia; Amino Acid Substitution; Animals; Cell Line, Transformed; Cell Line, Tumor; Chondrocytes; Cytoskeleton; Humans; Mice; Mutation; Paxillin; Phospholipase C gamma; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein Transport; Receptor, Fibroblast Growth Factor, Type 3; Recombinant Fusion Proteins; Signal Transduction; src-Family Kinases; Thanatophoric Dysplasia; Tyrosine | 2018 |
Effect of PPADS on achondroplasic chondrocytes: inhibition of FGF receptor type 3 over-activity.
Topics: Achondroplasia; Animals; Cell Line; Cell Survival; Chondrocytes; Dose-Response Relationship, Drug; Enzyme Activation; Extracellular Matrix; Fibroblast Growth Factor 9; Humans; Mesenchymal Stem Cells; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Phosphorylation; Protein Kinase Inhibitors; Purinergic P2 Receptor Antagonists; Pyridoxal Phosphate; Rats; Receptor, Fibroblast Growth Factor, Type 3; Receptors, Purinergic P2; Signal Transduction; Time Factors; Transfection; Tyrosine | 2008 |